Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2017 | The role of epigenetic modulators in the pathogenesis of lymphomas

Anas Younes, Eduardo Sotomayor, Laura Pasqualucci and Owen O'Connor • 18 Sep 2017
iwNHL 2017
Non-Hodgkin Lymphoma

Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY is joined by Eduardo Sotomayor, MD, from the George Washington University School of Medicine & Health Sciences, Washington, D.C, and Laura Pasqualucci, MD, from the Columbia University Medical Center, New York, NY, at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. They discuss the results of large sequencing studies, and the role of epigenetic modulators in the pathogenesis of lymphomas.

More from Anas Younes

1:01
Fimepinostat with venetoclax in R/R lymphoma
Anas Younes • 7 Dec 2019
1:27
Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes • 7 Dec 2019
1:42
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Anas Younes • 7 Dec 2019
2:55
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
Anas Younes • 6 Dec 2018

More from Laura Pasqualucci

New therapeutic targets in DLBCL
Ash Alizadeh et al. • 17 Oct 2023
10:20
The lymphoma tumor microenvironment: therapeutic targeting, genetics, drug optimization
Laura Pasqualucci et al. • 17 Sep 2019
12:46
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations
Andrew Zelenetz et al. • 23 Sep 2016

More from Owen O'Connor

6:47
Immunoepigenetic platforms for PTCL treatment
Owen O'Connor • 2 Jul 2019
4:42
PTCL arising as a PTLD: the efficacy of pralatrexate
Owen O'Connor • 19 Jun 2019
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al. • 8 Sep 2017
5:45
TGR-1202, novel PI3K delta inhibitor, for hematological malignancies
Owen O'Connor • 3 Oct 2015

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals